Montero Vergara J, Plachetta K, Kinch L, Bernhardt S, Kashyap K, Levine B, et al. GRB2 is a BECN1 interacting protein that regulates autophagy. Cell Death Dis. 2024;15:14 pubmed publisher

McKernan C, Khatri A, Hannigan M, Child J, Chen Q, Mayro B, et al. ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. Cell Rep. 2022;40:111268 pubmed publisher

Song X, Tang W, Peng H, Qi X, Li J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest New Drugs. 2021;: pubmed publisher

Akhand S, Chen H, Purdy S, Liu Z, Anderson J, Willey C, et al. Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. NPJ Breast Cancer. 2021;7:5 pubmed publisher

Reche Perez F, Plesselova S, De Los Reyes Berbel E, Ortega Muñoz M, López Jaramillo F, Hernandez Mateo F, et al. Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals. Biomater Sci. 2021;: pubmed publisher

Piasecka D, Braun M, Mieszkowska M, Kowalczyk L, Kopczynski J, Kordek R, et al. Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. Neoplasia. 2020;22:576-589 pubmed publisher

Kutys M, Polacheck W, Welch M, Gagnon K, Koorman T, Kim S, et al. Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Nat Commun. 2020;11:3377 pubmed publisher

DiScala M, Najor M, Yung T, Morgan D, Abukhdeir A, Cobleigh M. Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS ONE. 2020;15:e0234146 pubmed publisher

Wang M, LAW M, Davis B, Yaaghubi E, Ghilardi A, Ferreira R, et al. Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discov. 2019;5:153 pubmed publisher

Robichaux J, Elamin Y, Vijayan R, Nilsson M, Hu L, He J, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 2019;36:444-457.e7 pubmed publisher

Shin D, Jo J, Han J. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Mol Cancer Ther. 2018;17:2024-2033 pubmed publisher

Kitowska K, Kowalska A, Mieszkowska M, Piasecka D, Skladanowski A, Romanska H, et al. Progesterone impairs Herceptin effect on breast cancer cells. Oncol Lett. 2018;15:1817-1822 pubmed publisher

Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman J. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281-72301 pubmed publisher

Papadakis E, Barker C, Syed H, Reeves T, Schwaiger S, Stuppner H, et al. The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Oncogenesis. 2016;5:e215 pubmed publisher

Huang W, Burnouf P, Su Y, Chen B, Chuang K, Lee C, et al. Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS Nano. 2016;10:648-62 pubmed publisher

Garay C, Judge G, Lucarelli S, Bautista S, Pandey R, Singh T, et al. Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. Mol Biol Cell. 2015;26:3504-19 pubmed publisher

Greulich H, Kaplan B, Mertins P, Chen T, Tanaka K, Yun C, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012;109:14476-81 pubmed publisher